Vasovist

Food and Drug Administration marketing approval for MS-325 under the trade name Vasovist to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

unknown title 2009

MS-325 under the trade name Vasovist has been approved for marketing in the United States and in 37 countries outside the United States, including all 27 member states of the European Union, Norway, Iceland, Switzerland, Canada, Turkey, Australia, Korea,

unknown title 2009

EPIX received FDA approval for MS-325 as a first-in-class blood specific MRA contrast agent under the trade name Vasovist to evaluate aortoiliac occlusive disease (

Gadgets Sector and Stocks Analysis from Seeking Alpha 2009

EPIX received FDA approval for MS-325 as a first-in-class blood specific MRA contrast agent under the trade name Vasovist to evaluate aortoiliac occlusive disease (

Japan Stocks News and Analysis from Seeking Alpha 2009

The company sponsored FDA review of the drug "Vasovist."

Forbes.com: News Bill Singer 2011

The family of gadolinium-based imaging programs consists of MS-325 (gadofosveset trisodium), which is a commercial MRA imaging agent currently marketed as Ablavar (R) in the US by Lantheus Medical Imaging and formerly marketed as Vasovist (R) in Europe and other countries by Bayer Schering Pharma.

TradingMarkets 2010

Canadian and Australian Vasovist development costs.

unknown title 2009

EPIX and Bayer Schering Pharma had a collaboration and commercialization agreement for Vasovist that terminated as of February 28, 2009.

unknown title 2009

MS-325 (formerly marketed in the European Union, Canada and Switzerland as Vasovist by Bayer Schering Pharma AG, Germany) is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through magnetic resonance angiography imaging

unknown title 2009

These statements relate to, among other things, our expectations regarding the potential of PRX-03140, the monetization of Vasovist and management's plans, objectives and strategies.

unknown title 2009